Invesco
DNTH icon

Invesco’s Dianthus Therapeutics DNTH Stock Holding History

Invesco’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
130,747
+29,258
+29% +$1.69M ﹤0.01% 1782
2025
Q4 		$4.18M Buy
101,489
+56,560
+126% +$2.19M ﹤0.01% 2325
2025
Q3 		$1.77M Buy
44,929
+23,989
+115% +$613K ﹤0.01% 2666
2025
Q2 		$390K Buy
20,940
+4,962
+31% +$93.1K ﹤0.01% 3273
2025
Q1 		$290K Buy
15,978
+4,457
+39% +$98.2K ﹤0.01% 3368
2024
Q4 		$251K Buy
11,521
+790
+7% +$20.3K ﹤0.01% 3467
2024
Q3 		$294K Sell
10,731
-404
-4% -$11.3K ﹤0.01% 3426
2024
Q2 		$288K Buy
+11,135
New +$268K ﹤0.01% 3520
2022
Q2 		– Sell
-708
Closed -$33K – 4066
2022
Q1 		$33K Buy
708
+14
+2% +$765 ﹤0.01% 3958
2021
Q4 		$49K Sell
694
-116
-14% -$11.7K ﹤0.01% 3983
2021
Q3 		$95K Buy
810
+125
+18% +$14.6K ﹤0.01% 3948
2021
Q2 		$107K Buy
+685
New +$126K ﹤0.01% 3882
2019
Q2 		– Sell
-3,341
Closed -$880K – 3734
2019
Q1 		$880K Buy
+3,341
New +$576K ﹤0.01% 3087

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco's DNTH Position: Q1 2026 in Review

Invesco increased its Dianthus Therapeutics (DNTH) stake by 29% in Q1 2026, buying an estimated $1.69M and bringing the position to 130,747 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #1782.

Invesco first reported a position in DNTH in Q1 2019 and has held it in 13 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Invesco held 130,747 shares of Dianthus Therapeutics worth $11M as of Q1 2026.
  • Invesco bought 29,258 Dianthus Therapeutics shares in Q1 2026, an estimated $1.69M.
  • Dianthus Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1782 holding.
  • Invesco first reported a position in Dianthus Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.